Geant4 beam model for boron neutron capture therapy: investigation of neutron dose components

Modelling and validation of a 6 MV compact linear accelerator via Monte Carlo simulation using Geant4 Application for Tomographic Emission (GATE)

Objective. To accurately model and validate the 6 MV Elekta Compact linear accelerator using the Geant4 Application for Tomographic Emission (GATE). In particular, this study focuses on the precise calibration and validation of critical parameters, including jaw collimator positioning, electron source nominal energy, flattening filter geometry, and electron source spot size, which are often not provided in technical documentation.Methods. Simulation of the Elekta CompactTM6 MV linear accelerator was performed using the Geant4 Application for Tomographic Emission (GATE) v.9.1. A 50 cm × 50 cm × 50 cm water phantom was irradiated with a source-to-surface distance of 100 cm. Percentage Depth Dose Profile (PDD) and Lateral Dose Profile (Crossplane and Inplane) were assessed as reference dose measurements. The half-length field difference (FHLD) method was introduced to optimize the jaw collimator setup. Gamma index analysis was used to quantitatively assess the accuracy of the simulated dosimetry data in relation to the actual dose measurements.Results. Crucial parameters of the Linac Head have been successfully optimized. The validation achieved Gamma-Index acceptance rates of 97.93% for the Depth Dose profile, 100% for the Crossplane (X) Dose Profile, and 93.98% for the Inplane (Y) Dose Profile, all meeting the 1%/1 mm Gamma-Index criteria.Conclusion. The simulation and calibration of the Elekta Compact Linac have achieved a reliable model with high fidelity in dosimetry calculations which could pave the way for the future development and application of new techniques using Elekta CompactTMLinear Accelerator.

An Integrated Monte Carlo Model for Heterogeneous Glioblastoma Treated with Boron Neutron Capture Therapy

BACKGROUND

Glioblastomas (GBMs) are notorious for their aggressive features, e.g., intrinsic radioresistance, extensive heterogeneity, hypoxia, and highly infiltrative behaviours. The prognosis has remained poor despite recent advances in systemic and modern X-ray radiotherapy. Boron neutron capture therapy (BNCT) represents an alternative radiotherapy technique for GBM. Previously, a Geant4 BNCT modelling framework was developed for a simplified model of GBM.

PURPOSE

The current work expands on the previous model by applying a more realistic in silico GBM model with heterogeneous radiosensitivity and anisotropic microscopic extensions (ME).

METHODS

Each cell within the GBM model was assigned an α/β value associated with different GBM cell lines and a 10B concentration. Dosimetry matrices corresponding to various MEs were calculated and combined to evaluate cell survival fractions (SF) using clinical target volume (CTV) margins of 2.0 & 2.5 cm. SFs for the BNCT simulation were compared with external X-ray radiotherapy (EBRT) SFs.

RESULTS

The SFs within the beam region decreased by more than two times compared to EBRT. It was demonstrated that BNCT results in markedly reduced SFs for both CTV margins compared to EBRT. However, the SF reduction as a result of the CTV margin extension using BNCT was significantly lower than using X-ray EBRT for one MEP distribution, while it remained similar for the other two MEP models.

CONCLUSIONS

Although the efficiency of BNCT in terms of cell kill is superior to EBRT, the extension of the CTV margin by 0.5 cm may not increase the BNCT treatment outcome significantly.

Enhancement of Radiation Effectiveness in Proton Therapy: Comparison Between Fusion and Fission Methods and Further Approaches

Proton therapy as a promising candidate in cancer treatment has attracted much attentions and many studies have been performed to investigate the new methods to enhance its radiation effectiveness. In this regard, two research groups have suggested that using boron isotopes will lead to a radiation effectiveness enhancement, using boron-11 agent to initiate the proton fusion reaction (P-BFT) and using boron-10 agent to capture the low energy secondary neutrons (NCEPT). Since, these two innovative methods have not been approved clinically, they have been recalculated in this report, discussed and compared between them and also with the traditional proton therapy to evaluate their impacts before the experimental investigations. The calculations in the present study were performed by Geant4 and MCNPX Monte Carlo Simulation Codes were utilized for obtaining more precision in our evaluations of these methods impacts. Despite small deviations in the results from the two MC tools for the NCEPT method, a good agreement was observed regarding the delivered dose rate to the tumor site at different depths while, for P-BFT related calculations, the GEANT4 was in agreement with the analytical calculations by means of the detailed cross-sections of proton-¹¹B fusion. Accordingly, both the methods generate excess dose rate to the tumor several orders of magnitude lower than the proton dose rate. Also, it was found that, the P-BFT has more significant enhancement of effectiveness, when compared to the NCEPT, a method with impact strongly depended on the tumor's depth. On the other hand, the advantage of neutron risk reduction proposed by NCEPT was found to give no considerable changes in the neutron dose absorption by healthy tissues.